2-tetrahydrothiophenemethylamine | 83171-40-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 2-tetrahydrothiophenemethylamine
• 英文别名: 2-thiolanylmethylamine；C-tetrahydrothiophen-2-yl-methylamine；C-tetrahydro[2]thienyl-methylamine；2-Aminomethyltetrahydrothiophene；(tetrahydrothiophen-2-yl)methylamine；Thiolan-2-ylmethanamine
• CAS: 83171-40-8
• 化学式: C₅H₁₁NS
• 分子量: 117.215
• InChiKey: FLHFMMKGHUKQHI-UHFFFAOYSA-N

物化性质

• 沸点：
  197.5±13.0 °C(Predicted)
• 密度：
  1.037±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-tetrahydrothiophenemethylamine 在 氯甲酸乙酯 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 125.5h， 生成 2-<(2-methoxy-5-sulfamoylbenzamido)methyl>-1-ethyltetrahydrothiophenium iodide
  参考文献：
  名称：

  Synthesis and D2 dopaminergic activity of pyrrolidinium, tetrahydrothiophenium, and tetrahydrothiophene analogs of sulpiride

  摘要：

  All of the existing dopamine receptor models recognize the amine nitrogen of agonist and antagonist drugs as playing a crucial role in receptor interactions. However, there has been some controversy as to which molecular form of the amine, charged or uncharged, is most important in these interactions. We have synthesized and examined the biological activity of permanently charged and permanently uncharged analogues of the dopaminergic antagonist, sulpiride. Sulpiride and the permanently charged pyrrolidinium (6,7) and tetrahydrothiophenium (9) analogues were able to antagonize the inhibitory effect of apomorphine on the K+-induced release of [3H]acetylcholine from striatal slices. In contrast, the permanently uncharged tetrahydrothiophene analogue 8 was inactive at concentrations up to 100 microM. Additionally, both sulpiride and the tetrahydrothiophenium analogue were able to displace [3H]spiperone from D2 binding sites, while the tetrahydrothiophene analogue was unable to produce any significant displacement. These results are consistent with our previous observations on permanently charged chlorpromazine analogues and provide further evidence that dopaminergic antagonists bind in their charged molecular forms to anionic sites on the D2 receptor.

  DOI：

  10.1021/jm00124a024
• 作为产物：
  描述：

  2,5-二氯戊胺盐酸盐 在 盐酸 、 sodium sulfide 、 氯甲酸乙酯 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 55.0h， 生成 2-tetrahydrothiophenemethylamine
  参考文献：
  名称：

  Synthesis and D2 dopaminergic activity of pyrrolidinium, tetrahydrothiophenium, and tetrahydrothiophene analogs of sulpiride

  摘要：

  All of the existing dopamine receptor models recognize the amine nitrogen of agonist and antagonist drugs as playing a crucial role in receptor interactions. However, there has been some controversy as to which molecular form of the amine, charged or uncharged, is most important in these interactions. We have synthesized and examined the biological activity of permanently charged and permanently uncharged analogues of the dopaminergic antagonist, sulpiride. Sulpiride and the permanently charged pyrrolidinium (6,7) and tetrahydrothiophenium (9) analogues were able to antagonize the inhibitory effect of apomorphine on the K+-induced release of [3H]acetylcholine from striatal slices. In contrast, the permanently uncharged tetrahydrothiophene analogue 8 was inactive at concentrations up to 100 microM. Additionally, both sulpiride and the tetrahydrothiophenium analogue were able to displace [3H]spiperone from D2 binding sites, while the tetrahydrothiophene analogue was unable to produce any significant displacement. These results are consistent with our previous observations on permanently charged chlorpromazine analogues and provide further evidence that dopaminergic antagonists bind in their charged molecular forms to anionic sites on the D2 receptor.

  DOI：

  10.1021/jm00124a024

文献信息

• Platinum(II) complexes with thiourea derivatives containing oxygen, sulfur or selenium in a heterocyclic ring: computational studies and cytotoxic properties
  作者：L. Fuks、E. Anuszewska、H. Kruszewska、A. Krówczyński、J. Dudek、N. Sadlej-Sosnowska

  DOI：10.1007/s11243-010-9375-9

  日期：2010.9

  Platinum(II) complexes with 1-(2-oxolanylmethyl)-2-thiourea, 1-(2-thiolanylmethyl)-2-thiourea and 1-(2-selenolanylmethyl)-2-thiourea were synthesized in order to compare their cytotoxic activities with those of the free thioureas. Their equilibrium geometries and bonding energies in the gas phase and in solution were calculated using density functional theory at the MPW1PW/LanL2DZ level. The IR spectra

  合成了铂 (II) 与 1-(2-oxolanylmethyl)-2-thiourea、1-(2-thiolanylmethyl)-2-thiourea 和 1-(2-selenolanylmethyl)-2-thiourea 的配合物，以比较它们的细胞毒活性与那些游离硫脲。它们在气相和溶液中的平衡几何形状和键能是使用密度泛函理论在 MPW1PW/LanL2DZ 水平上计算的。比较了配合物及其游离配体的红外光谱。通过HPLC测试复合物在0.9%盐水溶液中的稳定性。评估了该物种对五种人类细胞系的细胞毒活性，以及​​对十二种细菌菌株的抗微生物活性。
• Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
  申请人：Farthing N. Christopher

  公开号：US20060040965A1

  公开（公告）日：2006-02-23

  Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.

  本文描述了调节ACK1和LCK作用的化合物以及相关组合物和治疗ACK1和LCK介导疾病的方法。在一个方面，这些化合物具有以下一般结构：其中取代基的值在此处提供。
• Furanopyrimidines
  申请人：Buchanan Laird John

  公开号：US20060040961A1

  公开（公告）日：2006-02-23

  The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

  本发明涉及具有一般式I的呋喃嘧啶化合物及其立体异构体、互变异构体、溶剂化物、药学上可接受的盐和衍生物以及其前药。本发明还包括包含一种I式化合物的制药组合物，以及在哺乳动物中治疗各种疾病和病况的方法，包括炎症、抑制T细胞激活、增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、桥本氏甲状腺炎、干燥综合症、自身免疫性甲状腺功能亢进症、Addison病、自身免疫性疾病、肾小球肾炎、过敏性疾病、哮喘、花粉热、湿疹、癌症、结肠癌和胸腺瘤的方法，包括向哺乳动物中投与一种I式化合物的治疗有效量。本发明还涉及制造药物的方法，其包括一种或多种I式化合物。
• 一种生物基含磷阻燃剂及其制备方法和应用
  申请人：福建工程学院

  公开号：CN114085246A

  公开（公告）日：2022-02-25

  本发明公开了一种生物基含磷阻燃剂，结构通式为： 式中，n为1‑5的整数；R1为甲基、甲氧基、乙基、乙氧基、苯基或苯氧基；R2为 R为氧、氮或硫。制备方法：先将碱性生物基环状化合物溶于有机溶剂中，加入缚酸剂，逐滴加入磷酰化合物，同时进行第一次反应，然后加热进行第二次反应，最后经过滤、洗涤、减压蒸馏和干燥，即得。本发明生物基含磷阻燃剂制备方法简单，原料廉价，产物纯度高，阻燃效果好，易于工业生产，可用于制备聚乳酸和环氧树脂材料，能够显著提高复合材料的阻燃性能。
• Putochin; Egorowa, Zhurnal Obshchei Khimii, 1948, vol. 18, p. 1866,1867
  作者：Putochin、Egorowa

  DOI：——

  日期：——